Enzo Biochem Q3 Revenues Rise 6 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Enzo Biochem said on Monday that its revenues for its fiscal third quarter were up 6 percent year over year.

For the three months ended April 30, the company reported total revenues of $24 million, up from $22.6 million in the year-ago quarter. Enzo's Clinical Labs segment revenues rose to 9 percent $14.5 million from $13.4 million, while Life Science product revenues increased 5 percent to $8.7 million from $8.3 million. Royalty and licensing fee income slid to $729,000 from $949,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.